Expert Discusses the Role of PD-L1 Expression as a Predictive Biomarker in Urothelial Carcinoma
Robert Dreicer, MD, discusses the role of biomarkers to predict response to immunotherapy in patients with urothelial carcinoma. He highlights the current status of using PD-L1 expression as a predictive biomarker to immunotherapy.
Robert Dreicer, MD, associate director for clinical research and the deputy director of the University of Virginia Cancer Center, discusses the role of biomarkers to predict response to immunotherapy in patients with urothelial carcinoma. He highlights the current status of using PD-L1 expression as a predictive biomarker to immunotherapy.
PD-L1 expression is not necessarily useful in deciding which patients with urothelial carcinoma will respond to checkpoint inhibition because patients that don’t express PD-L1 can still respond to this type of therapy, Dreicer says. However,an FDA guidance says that PD-L1 expression may be useful when treating patientsin the frontline with single-agent checkpoint inhibitors and that patients who are platinum eligible and have low PD-L1 expression should not receive immune checkpoint inhibitor monotherapy.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
